An Approach of Developing Floating Tablet of Lisinopril

  • Nidhi Jain Department of Pharmacy, Barkatullah University, Bhopal, Madhya Pradesh462026, India
  • Rahul Gupta Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India

Abstract

Lisinopril is an antihypertensive agent with 12 hr half life, pH-dependent solubility, and narrow absorption window. So, the present study aimed to prolong its gastric residence time that entailed a development of an optimized gastro retentive floating tablets (GRFTs). The tablets were fabricated by direct compression using hydroxypropyl methylcellulose and carbopol 934 as release retarding polymers. The quality attributes of the tablets were evaluated. The buoyancy lag time, total floating time, swelling ability and in vitro release studies were al so carried out in 0.1 N HCl (pH 1.2) at 37 ± 0.5 °C. Statistical data analysis revealed that the optimized formulation containing 21.91% HPMC and 15% carbopol 934 had acceptable hardness, optimum floating behavior and 24h controlled-release pattern. The design succeeded to develop CVD-GRFTs with floating ability and controlled release behavior that could improve its solubility, and improve its availability at the best absorptive site.

Keywords: Floating tablet, Dissolution studies, HPMC, floating lag time

References

1.Kurra N, Baru CR, Dhara V, Kumar VP. Formulation and evaluation of fast dissolving sublingual lisinopril tablets. IAJPS. 2014; 1: 378-391.
2.Lancaster SG, Todd PA. Lisinopril: A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs. 1988; 35: 646-669.
3.Gupta R, Mishra AK, Pathak AK. A critical review on different pharmaceutical aspects of solid dispersion technique for solubility enhancement. Int J Pharm Biol Sci. 2015; 5: 119–128.
4.Kumari K, Sharma P, Gupta R. Polysorbate-Phospholipid Complex Micelles as P-glycoprotein Inhibitor Drug Delivery System. J B Pharmaco Toxi. 2017; 1: 2-7.
5.Menon A, Ritschel WA, Sakr A. Development and Evaluation of monlolithic floating dosage form for furosemide. J Pharma Sci. 1994; 83: 239-245.
6.Kamble S, Ghorpade P. Gastro-Retentive Floating Drug Delivery System Containing Antihypertensive Drug-An Overview. W J Pharma Res. 2014; 3: 1076-1092.
7.Hamman JH, Demana PH, Olivier EI. Targeting Receptors, Transporters and Site of Absorption to Improve Oral Drug Delivery. Drug Tar Ins. 2007; 2: 71–81.
8.Garg R, Gupta GD. Progress in Controlled Gastroretentive Delivery Systems. T J Pharm Res. 2008; 7: 1055-1066.
9.Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating Drug Delivery Systems: A Review. AAPS Pharm Sci Tech. 2005; 6: 372- 390.
10.Jose GR, Khalid US. Gastric Retention of Solid Dosage Forms: A Review of the Current Climate. AAPS Pharm Sci Tech. 2004; 10: 22-23.
11.Sharma R, Gupta R, Jhat RK. Development and evaluation of sustained release bilayer matrix tablet of glipizide and metformin hydro chloride. Int J Drug Res Technol. 2013; 3: 60–66.
12.Jain A, Jain P, Jain SK, Agrawal RK, Agrawal GP. Calcium-silicate-based floating granular delivery system of ranitidine hydrochloride for effective management of peptic ulcer. Med Chem Res. 2008; 17: 305–317.
Statistics
57 Views | 46 Downloads
How to Cite
Jain, N., and R. Gupta. “An Approach of Developing Floating Tablet of Lisinopril”. Current Research in Pharmaceutical Sciences, Vol. 6, no. 4, Dec. 2016, pp. 86-92, http://crpsonline.com/index.php/crps/article/view/167.
Section
Research Articles